USA flag logo/image

An Official Website of the United States Government

SBIR TOPIC 283 PHASE I - DEVELOPMENT OF A MOLECULAR DIAGNOSTIC ASSAY TO DETECT…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
N43CO110089
Solicitation Year:
2011
Solicitation Topic Code:
NCI
Solicitation Number:
Small Business Information
Environmental Metrology Corporation
6595 North Oracle Road Suite 153B Tucson, AZ 85704-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: SBIR TOPIC 283 PHASE I - DEVELOPMENT OF A MOLECULAR DIAGNOSTIC ASSAY TO DETECT BASAL-LIKE BREAST CANCER
Agency: HHS
Contract: N43CO110089
Award Amount: $149,622.00
 

Abstract:

A molecular diagnostic test based on immunohistochemical detection of a characteristic protein biomarker will be developed to diagnose basal-like breast cancer (BLBC), similar to those already in routine use for detection of estrogen receptor and human epidermal growth factor receptor 2 (HER2) in breast cancer. The assay will be based on the detection of transcription factor FOXC1 protein utilizing a novel monoclonal antibody optimized for use on formalin-fixed paraffin-embedded breast tumor tissue. FOXC1 has recently been demonstrated by our group to be a characteristic, highly specific tissue level biomarker of BLBC. FOXC1 is also a potential therapeutic target by virtue of its demonstrated critical role in coordinating aggressive cancer traits. This proposal is focused on demonstrating and establishing the proof-of-concept of such a molecular diagnostic assay for the accurate detection of BLBC. Successful completion of this Phase I study is essential prior to undertaking large scale clinical validation ofthis diagnostic test in Phase II. If successfully validated, the molecular diagnostic test based on FOXC1 protein expression would greatly simplify the diagnosis of BLBC in routine clinical practice owing to the low cost and ease of integration of the proposed testing system into currently existing clinical pathology practice.

Principal Investigator:

Roberto Fagnani
908-625-5169
ROBERTO.FAGNANI@SAN.RR.COM

Business Contact:

Roberto Fagnani
908-625-5169
ROBERTO.FAGNANI@SAN.RR.COM
Small Business Information at Submission:

ORACLE BIOSCIENCES LLC
509 W UNIVERSITY AVE URBANA, IL 61801-1645

EIN/Tax ID: 999999999
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: Yes
HUBZone-Owned: No